Patrick Soon-Shiong adjusts ImmunityBio (IBRX) stake via RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ImmunityBio director and major holder Patrick Soon-Shiong reported vesting of restricted stock units and related share movements. On February 22, 2026, 114,329 restricted stock units were exercised into an equal number of common shares at $0.00 per share. To cover tax obligations, 58,170 common shares were disposed of at $8.70 per share through share withholding, leaving 29,757,911 common shares held directly after these transactions. Additional large blocks of ImmunityBio common stock are reported as held indirectly through affiliated entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile, and NantCancerStemCell, over which the reporting person may be deemed to have voting and dispositive power as described in the footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
114,329 shares exercised/converted
Mixed
11 txns
Insider
SOON-SHIONG PATRICK, CALIFORNIA CAPITAL EQUITY, LLC, Cambridge Equities, LP, MP 13 Ventures, LLC, Nant Capital, LLC
Role
See remarks | 10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 114,329 | $0.00 | -- |
| Exercise | Common Stock | 114,329 | $0.00 | -- |
| Tax Withholding | Common Stock | 58,170 | $8.70 | $506K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 114,329 shares (Direct);
Common Stock — 29,816,081 shares (Direct);
Common Stock — 246,412,277 shares (Indirect, See footnote)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld. Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person ("Nant Capital"). Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The Reporting Person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities. Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio. Shares held by California Capital Equity, LLC ("CalCap"). The Reporting Person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap. Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the Reporting Person by virtue of the reporting person's control over the Foundation. The rReporting Person serves as Chairman of the Foundation. Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The Reporting Person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks. Shares held by NantMobile, LLC ("NantMobile"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile. Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
FAQ
What insider transactions did Patrick Soon-Shiong report for ImmunityBio (IBRX)?
Patrick Soon-Shiong reported RSU vesting that converted 114,329 restricted stock units into ImmunityBio common shares. To satisfy tax obligations, 58,170 common shares were disposed of via share withholding at $8.70 per share, with the remaining shares added to his direct holdings.
What do the RSU terms disclosed for ImmunityBio (IBRX) indicate?
The RSU award vests over three years, subject to the reporting person continuing as a Service Provider. According to the disclosure, 33.33% vests on each of the first and second anniversaries, and 33.34% on the third, with a vesting commencement date of February 22, 2024.